Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment

2017 ◽  
Vol 27 (1) ◽  
pp. e12729 ◽  
Author(s):  
Ulla-Sisko Lehto ◽  
Arpo Aromaa ◽  
Teuvo L. Tammela
Keyword(s):  
Prostate Cancer ◽  
Psychological Distress ◽  
Cancer Patients ◽  
Primary Treatment

scholarly journals Primary Treatment Choice Over Time and Relative Survival of Prostate Cancer Patients: Influence of Age, Grade, and Stage

2017 ◽  
Vol 40 (9) ◽  
pp. 484-489 ◽  
Author(s):  
Katarina L. Matthes ◽  
Manuela Limam ◽  
Silvia Dehler ◽  
Dimitri Korol ◽  
Sabine Rohrmann
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Relative Survival ◽  
Primary Treatment ◽  
Treatment Choice ◽  
Over Time

scholarly journals Prostate cancer patients’ quality of life assessments across the primary treatment trajectory: ‘True’ change or response shift?

2016 ◽  
Vol 55 (7) ◽  
pp. 814-820 ◽  
Author(s):  
Christian Gerlich ◽  
Michael Schuler ◽  
Matthias Jelitte ◽  
Silke Neuderth ◽  
Michael Flentje ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cancer Patients ◽  
Response Shift ◽  
Primary Treatment

Risk of Cardiovascular Mortality in Prostate Cancer Patients in the Rotterdam Randomized Screening Trial

2006 ◽  
Vol 24 (25) ◽  
pp. 4184-4189 ◽  
Author(s):  
Suzie J. Otto ◽  
Fritz H. Schröder ◽  
Harry J. de Koning
Keyword(s):  
Prostate Cancer ◽  
General Population ◽  
Cancer Patients ◽  
Cardiovascular Mortality ◽  
Randomized Study ◽  
Primary Treatment ◽  
Treatment Modalities ◽  
Prostate Cancer Treatment ◽  
Standardized Mortality Ratios

Purpose To estimate the risk of cardiovascular disease (CVD) mortality in prostate cancer patients in the Rotterdam section of European Randomized Study of Screening for Prostate Cancer, in both arms, and to compare this with the risk in the general population. Methods Standardized mortality ratios (SMRs) of cardiovascular mortality for 2,211 prostate cancer patients were calculated including analyses for treatment subgroups (surgery, radiotherapy, watchful waiting, and hormone therapy). Cardiovascular mortality was defined as death as a result of all CVD and as a result of coronary heart disease, acute myocardial infarction, other diseases of the heart, and cerebrovascular accidents. The prevalence of self-reported comorbidities at entry of the trial was evaluated as well. Results After a mean follow-up of 5.5 years, 258 prostate cancer patients (12%) had died. The SMR of all-cause mortality was 0.90 (95% CI, 0.79 to 1.01). The risk for cardiovascular mortality was low compared with that in the general population; the SMRs varied between 0.37 and 0.49. Low cardiovascular mortality risks were also seen within each treatment subgroup. CVD was the most frequently self-reported comorbidity at entry and prostate cancer patients undergoing radical prostatectomy reported the lowest rates (24%) compared with those receiving other therapies (40% to 42%). Conclusion Although some self-selection has occurred, prostate cancer treatment did not increase the risk of dying as a result of cardiovascular causes in our cohort. The risk was significantly lower for all primary treatment modalities, suggesting that less emphasis should be put on CVD as a contraindication for aggressive (surgical) treatment for prostate cancer patients.

Role of Metastasectomy in Prostate Cancer Patients Following Primary Treatment

2020 ◽  
pp. 211-221
Author(s):  
Gaëtan Devos ◽  
Antonino Battaglia ◽  
Lorenzo Tosco ◽  
Wouter Everaerts ◽  
Charlien Berghen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Primary Treatment
Sign in / Sign up

Export Citation Format

Share Document